{'fraction_non_alphanumeric': 0.033950617283950615, 'fraction_numerical': 0.0257201646090535, 'mean_word_length': 5.443708609271523, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome.

OBJECTIVES
To determine whether taking Hydroxychloroquine could prevent the development of new-onset diabetes mellitus among patients with Sjögren syndrome.


METHODS



RESULTS
Patients with Sjögren syndrome treated with Hydroxychloroquine had a significantly lower cumulative incidence of new-onset diabetes mellitus than those not treated with Hydroxychloroquine (adjusted hazard ratio: 0.51, 95% confidence interval: 0.28-0.96, p < 0.05). Hydroxychloroquine use for 3 years or more had favorable protective effects (adjusted hazard ratio: 0.22, confidence interval: 0.05-0.92).


CONCLUSIONS
Hydroxychloroquine reduced the incidence of diabetes mellitus in a time and dose-dependent manner. Patients with SS who had taken Hydroxychloroquine for 3 years or more exhibited significant protective effects against developing new-onset diabetes mellitus.